Ginkgo Bioworks Valued At $15B In SPAC Deal Led By 3 Firms
Ginkgo Bioworks will hit the public markets at a pre-money valuation of $15 billion by merging with a special purpose acquisition vehicle backed by former Metro-Goldwyn-Mayer Studios and CBS executives, the...To view the full article, register now.
Already a subscriber? Click here to view full article